Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 4/2020

01-10-2020 | Care | Original Article

Surveillance of Transfusion Related Adverse Reactions in a Tertiary Care Centre in Bangalore: A 4-Year Hemovigilance Initiative

Author: Shweta Pai

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 4/2020

Login to get access

Abstract

Even though blood transfusion is a life saving measure, it is nonetheless associated with a number of risks and hazards. The adverse reactions that can be potentially expected range anywhere in severity from mild to life threatening. The hemovigilance program deals with the systematic surveillance of these reactions as and when they occur in a hospital setting with an explicit aim of improving the quality and safety standards of the entire transfusion process. The current study was undertaken in the blood bank of a tertiary care centre in Bangalore to ascertain frequency of the blood transfusion related adverse reactions and to make a systematic profile assessment. Data was collected over a period of 4 years and 3 months. All adverse reactions caused by transfusion of blood and its products during the study period were included in the study. A total of 6910 units of blood and its components were issued to patients during the study period. Transfusion reactions accounted for 0.5% of transfusions. Febrile non-hemolytic transfusion reactions were the most common reactions (51.4%) followed by allergic reactions (40%), fluid overload (5.7%) and anaphylactic reactions (2.9%). Majority of these reactions were seen with PRBC transfusions (74.3%) followed by platelet transfusions (25.7%). The use of leukoreduced PRBCs will help in reducing the frequency of these reactions. The hemovigilance program of our institution helps in assessing the diversity of adverse reactions associated with transfusion of blood and its various components. It is also an efficient scheme for minimizing their occurrence by ensuring safety standards.
Literature
1.
go back to reference Pai S (2019) Seroprevalence and trend of transfusion transmitted infections among blood donors in the eastern part of Bangalore city: a 3-year study. J Diagn Pathol Oncol 4(3):221–225CrossRef Pai S (2019) Seroprevalence and trend of transfusion transmitted infections among blood donors in the eastern part of Bangalore city: a 3-year study. J Diagn Pathol Oncol 4(3):221–225CrossRef
2.
go back to reference Faber JC (2004) Worldwide overview of existing hemovigilance system. Transfus Apher Sci 31:99–110CrossRef Faber JC (2004) Worldwide overview of existing hemovigilance system. Transfus Apher Sci 31:99–110CrossRef
3.
go back to reference Stainsby D, Faber JC, Jorgensen J (2009) Overview of hemovigilance. In: Simon TL (ed) Rossi’s principle of transfusion medicine, 4th edn. Wiley-Blackwell Publishers, Hoboken, pp 681–698CrossRef Stainsby D, Faber JC, Jorgensen J (2009) Overview of hemovigilance. In: Simon TL (ed) Rossi’s principle of transfusion medicine, 4th edn. Wiley-Blackwell Publishers, Hoboken, pp 681–698CrossRef
4.
go back to reference Bisht A, Singh S, Marwaha N (2013) Hemovigilance program-India. Asian J Transfus Sci 7:73–74CrossRef Bisht A, Singh S, Marwaha N (2013) Hemovigilance program-India. Asian J Transfus Sci 7:73–74CrossRef
5.
go back to reference Lichtiger B, Perry-Thomton E (1984) Hemolytic transfusion reactions in oncology patients: experience in a large cancer centre. J Clin Oncol 2:438–442CrossRef Lichtiger B, Perry-Thomton E (1984) Hemolytic transfusion reactions in oncology patients: experience in a large cancer centre. J Clin Oncol 2:438–442CrossRef
6.
go back to reference Heddle NM, Blajchman MA, Meyer RM, Lipton JH, Walker IR, Sher GD et al (2002) A randomized controlled trial comparing the frequency of acute reactions toplasma-removed platelets and prestorage WBC- reduced platelets. Transfusion 42:556–566CrossRef Heddle NM, Blajchman MA, Meyer RM, Lipton JH, Walker IR, Sher GD et al (2002) A randomized controlled trial comparing the frequency of acute reactions toplasma-removed platelets and prestorage WBC- reduced platelets. Transfusion 42:556–566CrossRef
7.
go back to reference Pilli GS (2012) Transfusion reactions. In: Pilli GS (ed) Blood banking and transfusion medicine, 1st edn. KLE University, Belgaum, pp 54–68 Pilli GS (2012) Transfusion reactions. In: Pilli GS (ed) Blood banking and transfusion medicine, 1st edn. KLE University, Belgaum, pp 54–68
8.
go back to reference Kuriyan M, Carson JL (2004) Blood transfusion risks in the intensive care unit. Crit Care Clin 20:237–253CrossRef Kuriyan M, Carson JL (2004) Blood transfusion risks in the intensive care unit. Crit Care Clin 20:237–253CrossRef
9.
go back to reference Callum JL, Pinkerton PH (2005) Transfusion reactions. In: Callum JL, Pinkerton PH (eds) Bloody easy: blood transfusions, blood alternatives and transfusion reactions, a guide to transfusion medicine, 4th edn. Sunnybrook and Women’s College Health Sciences Centre, Toronto, pp 34–65 Callum JL, Pinkerton PH (2005) Transfusion reactions. In: Callum JL, Pinkerton PH (eds) Bloody easy: blood transfusions, blood alternatives and transfusion reactions, a guide to transfusion medicine, 4th edn. Sunnybrook and Women’s College Health Sciences Centre, Toronto, pp 34–65
10.
go back to reference Gao Y, Li Q, Gao Z, Zhu Y, Zhu C, Sun Y et al (2015) Meta-analysis of incidence of adverse transfusion reaction in clinical cases in China. SM J Clin Med 1:1005 Gao Y, Li Q, Gao Z, Zhu Y, Zhu C, Sun Y et al (2015) Meta-analysis of incidence of adverse transfusion reaction in clinical cases in China. SM J Clin Med 1:1005
11.
go back to reference Sharma DK, Datta S, Gupta A (2015) Study of acute transfusion reactions in a teaching hospital of Sikkim: a hemovigilance initiative. Indian J Pharmacol 47:370–374CrossRef Sharma DK, Datta S, Gupta A (2015) Study of acute transfusion reactions in a teaching hospital of Sikkim: a hemovigilance initiative. Indian J Pharmacol 47:370–374CrossRef
12.
go back to reference Kumar R, Gupta M, Gupta V, Kaur A, Gupta S (2014) Acute transfusion reactions (ATRs) in intensive care unit (ICU): a retrospective study. J Clin Diagn Res 8:127–129PubMedPubMedCentral Kumar R, Gupta M, Gupta V, Kaur A, Gupta S (2014) Acute transfusion reactions (ATRs) in intensive care unit (ICU): a retrospective study. J Clin Diagn Res 8:127–129PubMedPubMedCentral
13.
go back to reference Bhattacharya P, Marwaha N, Dhawan HK, Roy P, Sharma RR (2011) Transfusion-related adverse events at the tertiary care center in North India: an institutional hemovigilance effort. Asian J Transfus Sci 5:164–170CrossRef Bhattacharya P, Marwaha N, Dhawan HK, Roy P, Sharma RR (2011) Transfusion-related adverse events at the tertiary care center in North India: an institutional hemovigilance effort. Asian J Transfus Sci 5:164–170CrossRef
14.
go back to reference Kumar P, Thapliyal R, Coshic P, Chatterjee K (2013) Retrospective evaluation of adverse transfusion reactions following blood product transfusion from a tertiary care hospital: a preliminary step towards hemovigilance. Asian J Transfus Sci 7:109–115CrossRef Kumar P, Thapliyal R, Coshic P, Chatterjee K (2013) Retrospective evaluation of adverse transfusion reactions following blood product transfusion from a tertiary care hospital: a preliminary step towards hemovigilance. Asian J Transfus Sci 7:109–115CrossRef
15.
go back to reference Michlig C, Vu DH, Wasserfallen JB, Spahn DR, Schneider P, Tissot JD (2003) Three years of haemovigilance in a general university hospital. Transfus Med 13:63–72CrossRef Michlig C, Vu DH, Wasserfallen JB, Spahn DR, Schneider P, Tissot JD (2003) Three years of haemovigilance in a general university hospital. Transfus Med 13:63–72CrossRef
16.
go back to reference Robillard P, Nawej KI, Jochem K (2004) The Quebec hemovigilance system: description and results from the first two years. Transfus Apher Sci 31:111–122CrossRef Robillard P, Nawej KI, Jochem K (2004) The Quebec hemovigilance system: description and results from the first two years. Transfus Apher Sci 31:111–122CrossRef
17.
go back to reference Khalid S, Usman M, Khurshid M (2010) Acute transfusion reactions encountered in patients at a tertiary care center. J Pak Med Assoc 60:832–836PubMed Khalid S, Usman M, Khurshid M (2010) Acute transfusion reactions encountered in patients at a tertiary care center. J Pak Med Assoc 60:832–836PubMed
18.
go back to reference Mafirakureva N, Khoza S, Mvere DA, Chitiyo ME, Postma MJ, Van Hulst M (2014) Incidence and pattern of 12 years of reported transfusion adverse events in Zimbabwe: a retrospective analysis. Blood Transfus 12:362–367PubMedPubMedCentral Mafirakureva N, Khoza S, Mvere DA, Chitiyo ME, Postma MJ, Van Hulst M (2014) Incidence and pattern of 12 years of reported transfusion adverse events in Zimbabwe: a retrospective analysis. Blood Transfus 12:362–367PubMedPubMedCentral
19.
go back to reference Khoyumthem P, Rachandra K, Goswami S, Lyngdoh LN, Sharma AB, Singh AM (2018) Acute transfusion reactions in a tertiary hospital: a 2-year retrospective study. J Med Soc 32:47–50CrossRef Khoyumthem P, Rachandra K, Goswami S, Lyngdoh LN, Sharma AB, Singh AM (2018) Acute transfusion reactions in a tertiary hospital: a 2-year retrospective study. J Med Soc 32:47–50CrossRef
20.
go back to reference Sidhu M, Meenia R, Yasmeen I, Akhtar N (2015) A study of transfusion related adverse events at a tertiary care centre in North India: an initiative towards hemovigilance. Int J Adv Med 2:206–210CrossRef Sidhu M, Meenia R, Yasmeen I, Akhtar N (2015) A study of transfusion related adverse events at a tertiary care centre in North India: an initiative towards hemovigilance. Int J Adv Med 2:206–210CrossRef
21.
go back to reference Payandeh M, Zare ME, Kansestani AN, Pakdel SF, Jahanpour F, Yousefi H et al (2013) Descriptions of acute transfusion reactions in the teaching hospitals of Kermanshah university of medical sciences, Iran. Int J Hematol Oncol Stem Cell Res 7:11–16PubMedPubMedCentral Payandeh M, Zare ME, Kansestani AN, Pakdel SF, Jahanpour F, Yousefi H et al (2013) Descriptions of acute transfusion reactions in the teaching hospitals of Kermanshah university of medical sciences, Iran. Int J Hematol Oncol Stem Cell Res 7:11–16PubMedPubMedCentral
22.
go back to reference Savage WJ, Tobian AA, Savage JH, Wood RA, Schroeder JT, Ness PM (2013) Scratching the surface of allergic transfusion reactions. Transfusion 53:1361–1371CrossRef Savage WJ, Tobian AA, Savage JH, Wood RA, Schroeder JT, Ness PM (2013) Scratching the surface of allergic transfusion reactions. Transfusion 53:1361–1371CrossRef
23.
go back to reference Kleinman S, Chan P, Robillard P (2003) Risk associated with transfusion of cellular blood component in Canada. Transfus Med Rev 17:120–162CrossRef Kleinman S, Chan P, Robillard P (2003) Risk associated with transfusion of cellular blood component in Canada. Transfus Med Rev 17:120–162CrossRef
24.
go back to reference Robillard P, Karl IN (2002) Incidence of adverse transfusion reactions in the Quebec hemovigilance system. Vox Sang 83:120 Robillard P, Karl IN (2002) Incidence of adverse transfusion reactions in the Quebec hemovigilance system. Vox Sang 83:120
25.
go back to reference Popovsky MA, Taswell RF (2002) Circulatory overload: an underdiagnosed consequence of transfusion. Vox Sang 83:469CrossRef Popovsky MA, Taswell RF (2002) Circulatory overload: an underdiagnosed consequence of transfusion. Vox Sang 83:469CrossRef
Metadata
Title
Surveillance of Transfusion Related Adverse Reactions in a Tertiary Care Centre in Bangalore: A 4-Year Hemovigilance Initiative
Author
Shweta Pai
Publication date
01-10-2020
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 4/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01312-w

Other articles of this Issue 4/2020

Indian Journal of Hematology and Blood Transfusion 4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine